News | February 24, 2026
Bayer introduces chemo-free treatment option for advanced prostate cancer in India
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Subscribe To Our Newsletter & Stay Updated
